NEW YORK, NY / ACCESSWIRE / May 23, 2016 / SeeThruEquity, a leading New York City based independent equity research and
corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on
Innovus Pharmaceuticals, Inc. (OTCQB: INNV).
The note is available here: INNV May 2016 Update Note. SeeThruEquity is an approved equity research contributor on Thomson First
Call, Capital IQ, FactSet, and Zack's. The report will be available on these platforms. The firm also contributes its estimates to
Thomson Estimates, the leading estimates platform on Wall Street.
Innovus Pharmaceuticals, Inc. (OTCBB: INNV, "Innovus") is an emerging commercial stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter (OTC) medicine and consumer care products to improve men and women's health,
respiratory disease and vitality. Innovus recently released 1Q16 results, which showed double-digit organic growth as well as
controlled operating expenses. The company recently completed the acquisition of Beyond Human™, which has expanded its pipeline to
include 13 commercialized products and three pipeline products, and has several upcoming key milestones on the horizon,
including:
- Fluticare™: Innovus management expects to hear from the FDA regarding its ANDA for Fluticare™, which is perhaps the
crown jewel of the company's pipeline, targeting what Innovus estimates is a $1Bn potential opportunity. - Strong Outlook: Innovus
has stated that it expects to more than triple FY15 sales in FY16, with the rise driven by a combination of growth in its
commercial products and the inclusion of Beyond Human™ in results. - Innovus continues to target an uplisting to a national
exchange, likely the NYSE Market - a goal reiterated by management in an announcement by the company on May 17, 21016.
Highlights of note are as follows:
FlutiCare™ decision a significant catalyst
Innovus management expects to hear from the FDA within the next 3-4 months regarding its significant pipeline product,
FlutiCare™, a nasal steroid spray for allergenic and non-allergenic rhinitis (hay fever / stuffy nose). The manufacturer filed an
Abbreviated New Drug Application (ANDA) with the FDA at the end of 2014, and an approval of would enable Innovus to market
FlutiCare™ over-the-counter (OTC) possibly as soon the end of 2016 / early 2017. Innovus sees a positive FlutiCare™ decision as
having transformative potential for the company. Indeed, if approved, FlutiCare would represent the company's largest market
opportunity; management estimates the addressable market for FlutiCare™ OTC commercial products as much as $1 billion per year,
which does not seem too aggressive considering 40mn doses were dispensed in 2014.
Health and Vitality portfolio has large potential
Beyond FlutiCare™ Innovus is also already targeting several large OTC markets for health and vitality, which the company
estimates represent a multi-billion dollar opportunity. These include female sexual arousal / satisfaction oil Zestra® and products
for Premature Ejaculation / Penile Sensitivity. Management believes it has products that target a billion-dollar plus market
opportunity in both men's and women's health / vitality. Indeed the company appears to be making progress in the early stages of
commercialization, given that Innovus has stated that it has signed eight commercial partnerships with over $500mn in sales
milestones plus royalties, in 60 countries.
Innovus price target increased to $0.91
We see Innovus as a high-risk / high-reward investment opportunity in the OTC pharmaceuticals space with a differentiated
business model focused on men and women's health and vitality. We are enthused by the growth and synergies enabled by the Beyond
Human acquisition, and eager to learn of the upcoming FDA decision for FlutiCare™.
Please review important disclosures at www.seethruequity.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and
vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c)
Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this
space, including (e) Sensum+® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra
Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male
reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for
Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.
About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market
capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission
based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet,
Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson
Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.
Contact:
Ajay TandonSeeThruEquityinfo@seethruequity.com
SOURCE: SeeThruEquity
